Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATVI Activision Blizzard	$94.42	$93.80	$70.94 ▼ $94.57	$74.29B	0.44	8.31 million shs	1 shs
GPN Global Payments	$78.88 -2.9%	$78.53	$65.93 ▼ $120.00	$19.81B	0.94	2.51 million shs	2.33 million shs
HR Healthcare Realty Trust	$16.09 -0.6%	$15.08	$14.09 ▼ $18.90	$5.66B	0.89	3.18 million shs	7.01 million shs
JELD JELD-WEN	$4.59 -1.3%	$3.97	$3.27 ▼ $17.70	$396.95M	1.69	1.15 million shs	939,771 shs
SUPN Supernus Pharmaceuticals	$33.12 -0.1%	$32.26	$27.05 ▼ $40.28	$1.85B	0.7	487,537 shs	461,128 shs

2025 Gold Forecast: A Perfect Storm for Demand

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATVI Activision Blizzard	0.00%	0.00%	0.00%	0.00%	0.00%
GPN Global Payments	-2.87%	-3.56%	-0.96%	-7.20%	-16.82%
HR Healthcare Realty Trust	-0.65%	+1.04%	+9.16%	+4.54%	-5.19%
JELD JELD-WEN	-1.40%	+3.38%	+16.06%	-12.14%	-65.10%
SUPN Supernus Pharmaceuticals	-0.06%	+3.52%	-0.09%	+4.58%	+20.52%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATVI Activision Blizzard	0.8232 of 5 stars	0.0	0.0	2.5	2.1	0.6	1.7	0.6
GPN Global Payments	4.9955 of 5 stars	4.1	5.0	2.5	2.3	4.0	1.7	4.4
HR Healthcare Realty Trust	3.4254 of 5 stars	0.9	5.0	1.7	3.7	2.6	1.7	0.6
JELD JELD-WEN	4.4675 of 5 stars	3.9	5.0	0.0	1.7	1.4	3.3	0.6
SUPN Supernus Pharmaceuticals	1.5132 of 5 stars	1.2	1.0	0.0	4.1	2.6	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATVI Activision Blizzard	0.00	N/A	N/A	N/A
GPN Global Payments	2.29	Hold	$111.09	40.84% Upside
HR Healthcare Realty Trust	1.80	Reduce	$16.40	1.96% Upside
JELD JELD-WEN	1.88	Reduce	$7.34	59.99% Upside
SUPN Supernus Pharmaceuticals	2.33	Hold	$36.00	8.70% Upside

Current Analyst Ratings Breakdown

Latest GPN, SUPN, JELD, HR, and ATVI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/9/2025	GPN Global Payments	Keefe, Bruyette & Woods Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Perform ➝ Market Perform	$81.00 ➝ $85.00
6/26/2025	HR Healthcare Realty Trust	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$18.00 ➝ $17.00
6/2/2025	GPN Global Payments	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold	$79.00
6/2/2025	HR Healthcare Realty Trust	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$16.00 ➝ $15.00
5/8/2025	JELD JELD-WEN	Loop Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$8.00 ➝ $4.00
5/8/2025	JELD JELD-WEN	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$5.00 ➝ $4.50
5/7/2025	GPN Global Payments	Keefe, Bruyette & Woods Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Perform ➝ Market Perform	$78.00 ➝ $81.00
5/7/2025	GPN Global Payments	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$80.00 ➝ $90.00
5/7/2025	GPN Global Payments	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$115.00 ➝ $85.00
5/7/2025	JELD JELD-WEN	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underperform ➝ Underperform	$5.00 ➝ $2.00
5/7/2025	JELD JELD-WEN	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$6.00 ➝ $5.25

(Data available from 7/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATVI Activision Blizzard	$8.71B	8.53	$3.38 per share	27.91	$24.59 per share	3.84
GPN Global Payments	$10.11B	1.90	$18.82 per share	4.19	$91.90 per share	0.86
HR Healthcare Realty Trust	$1.22B	4.63	$0.83 per share	19.42	$15.12 per share	1.06
JELD JELD-WEN	$3.78B	0.10	$3.23 per share	1.42	$7.33 per share	0.63
SUPN Supernus Pharmaceuticals	$668.00M	2.78	$4.17 per share	7.95	$18.76 per share	1.77

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATVI Activision Blizzard	$1.51B	$2.73	34.59	24.09	2.61	24.87%	14.87%	10.78%	N/A
GPN Global Payments	$1.57B	$6.20	12.72	5.85	0.78	15.48%	12.33%	5.82%	8/6/2025 (Estimated)
HR Healthcare Realty Trust	-$654.48M	-$1.09	N/A	9.87	N/A	-31.32%	-7.06%	-3.52%	8/1/2025 (Estimated)
JELD JELD-WEN	-$189.02M	-$4.03	N/A	∞	N/A	-9.49%	3.70%	0.88%	8/4/2025 (Estimated)
SUPN Supernus Pharmaceuticals	$73.86M	$1.11	29.84	23.00	N/A	9.27%	12.23%	9.17%	8/5/2025 (Estimated)

Latest GPN, SUPN, JELD, HR, and ATVI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	GPN Global Payments	$3.03	N/A	N/A	N/A	$2.36 billion	N/A
8/5/2025	Q2 2025	SUPN Supernus Pharmaceuticals	$0.47	N/A	N/A	N/A	$154.06 million	N/A
8/4/2025	Q2 2025	JELD JELD-WEN	-$0.03	N/A	N/A	N/A	$809.84 million	N/A
8/1/2025	Q2 2025	HR Healthcare Realty Trust	$0.40	N/A	N/A	N/A	$290.83 million	N/A
5/6/2025	Q1 2025	GPN Global Payments	$2.73	$2.82	+$0.09	$1.24	$2.20 billion	$2.20 billion
5/5/2025	Q1 2025	JELD JELD-WEN	-$0.19	-$0.17	+$0.02	-$2.12	$769.25 million	$776.00 million
5/1/2025	Q1 2025	HR Healthcare Realty Trust	$0.39	$0.39	N/A	$0.39	$297.39 million	$288.86 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATVI Activision Blizzard	$0.99	1.05%	N/A	36.26%	1 Years
GPN Global Payments	$1.00	1.27%	N/A	16.13%	N/A
HR Healthcare Realty Trust	$1.24	7.71%	N/A	N/A	N/A
JELD JELD-WEN	N/A	N/A	N/A	N/A	N/A
SUPN Supernus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Latest GPN, SUPN, JELD, HR, and ATVI Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/7/2025	GPN Global Payments	quarterly	$0.25	1.3%	6/13/2025	6/13/2025	6/27/2025
5/2/2025	HR Healthcare Realty Trust	quarterly	$0.31	8.2%	5/12/2025	5/12/2025	5/23/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATVI Activision Blizzard	0.17	4.66	4.66
GPN Global Payments	0.66	0.94	0.94
HR Healthcare Realty Trust	0.01	N/A	N/A
JELD JELD-WEN	2.56	1.87	1.12
SUPN Supernus Pharmaceuticals	N/A	2.44	2.26

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATVI Activision Blizzard	81.93%
GPN Global Payments	89.76%
HR Healthcare Realty Trust	N/A
JELD JELD-WEN	95.04%
SUPN Supernus Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
ATVI Activision Blizzard	1.08%
GPN Global Payments	1.01%
HR Healthcare Realty Trust	0.37%
JELD JELD-WEN	1.24%
SUPN Supernus Pharmaceuticals	8.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATVI Activision Blizzard	13,000	786.80 million	778.30 million	Optionable
GPN Global Payments	27,000	243.88 million	241.42 million	Optionable
HR Healthcare Realty Trust	580	351.42 million	350.12 million	Optionable
JELD JELD-WEN	16,000	85.37 million	84.31 million	Optionable
SUPN Supernus Pharmaceuticals	580	55.99 million	51.06 million	Optionable

GPN, SUPN, JELD, HR, and ATVI Headlines

Recent News About These Companies

Wall Street Zen Upgrades Supernus Pharmaceuticals (NASDAQ:SUPN) to Buy

July 12 at 2:42 AM | marketbeat.com

2 Cash-Heavy Stocks to Own for Decades and 1 to Approach with Caution

July 10 at 9:41 AM | finance.yahoo.com

Branded Pharmaceuticals Stocks Q1 Recap: Benchmarking Merck (NYSE:MRK)

July 9 at 5:15 AM | msn.com

Head-To-Head Analysis: Supernus Pharmaceuticals (NASDAQ:SUPN) & Personalis (NASDAQ:PSNL)

July 5, 2025 | americanbankingnews.com

Meritage Portfolio Management Acquires 10,622 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

July 4, 2025 | marketbeat.com

Supernus Pharmaceuticals, Inc. (SUPN) - Yahoo Finance

July 3, 2025 | finance.yahoo.com

8,151 Shares in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Bought by Robeco Institutional Asset Management B.V.

July 3, 2025 | marketbeat.com

Sage Sacks Entire Staff After Supernus Buyout

June 30, 2025 | biospace.comB

Supernus Pharmaceuticals’s Q1 Earnings Call: Our Top 5 Analyst Questions

June 27, 2025 | msn.com

Supernus Pharmaceuticals (NASDAQ:SUPN) shareholders have earned a 6.8% CAGR over the last five years

June 23, 2025 | uk.finance.yahoo.com

Supernus Pharmaceuticals (NASDAQ:SUPN) Lowered to Hold Rating by Wall Street Zen

June 21, 2025 | marketbeat.com

SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE

June 18, 2025 | businesswire.com

Supernus Pharma to Buy Sage Therapeutics for Up to $795 Million

June 16, 2025 | marketwatch.com

Supernus enters depression drug market with up to $795 million Sage deal

June 16, 2025 | msn.com

Supernus Pharmaceuticals Gets Retail Excited Over $795M Acquisition Plan For Sage Therapeutics

June 16, 2025 | msn.com

Supernus to acquire depression drugmaker Sage

June 16, 2025 | msn.com

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Sage Therapeutics, Inc.

June 16, 2025 | prnewswire.com

Supernus Pharmaceuticals (SUPN) to Acquire Sage Therapeutics in $795M Deal

June 16, 2025 | gurufocus.com

Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry ...

June 16, 2025 | gurufocus.com

Supernus Pharmaceuticals to Acquire Sage Therapeutics in a Strategic Move | SUPN stock news

June 16, 2025 | gurufocus.com

Sage Therapeutics Stock Soars 35% After Sale to Supernus Pharmaceuticals. What We Know.

June 16, 2025 | barrons.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
3 Stocks With Near-Unanimous Buys That Could Rally Higher
By Nathan Reiff | July 2, 2025
View 3 Stocks With Near-Unanimous Buys That Could Rally Higher
Which Analyst-Favorite Drone Stock Will Come Out on Top?
By Nathan Reiff | June 25, 2025
View Which Analyst-Favorite Drone Stock Will Come Out on Top?
Do They Know Something? Insiders & Congress Buy UnitedHealth
By Brian O'Connell | July 9, 2025
View Do They Know Something? Insiders & Congress Buy UnitedHealth

GPN, SUPN, JELD, HR, and ATVI Company Descriptions

Activision Blizzard NASDAQ:ATVI

Activision Blizzard, Inc., together with its subsidiaries, develops and publishes interactive entertainment content and services in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates through three segments: Activision, Blizzard, and King. It develops and distributes content and services on video game consoles, personal computers, and mobile devices, including subscription, full-game, and in-game sales, as well as by licensing software to third-party or related-party companies that distribute Activision and Blizzard products. The company also maintains a proprietary online gaming service, Battle.net that facilitates digital distribution of content, online social connectivity, and the creation of user-generated content. In addition, it operates esports leagues and offer digital advertising content; and provides warehousing, logistics, and sales distribution services to third-party publishers of interactive entertainment software, as well as manufacturers of interactive entertainment hardware products. The company's key product franchises include Call of Duty, World of Warcraft, Diablo, Hearthstone, Overwatch, Overwatch League, and Candy Crush. It serves retailers and distributors, including mass-market retailers, consumer electronics stores, discount warehouses, and game specialty stores through third-party distribution and licensing arrangements. The company was founded in 1979 and is headquartered in Santa Monica, California.

Global Payments NYSE:GPN

$78.88 -2.35 (-2.89%)

Closing price 07/11/2025 03:58 PM Eastern

Extended Trading

$79.99 +1.11 (+1.41%)

As of 07/11/2025 07:26 PM Eastern

Global Payments Inc. provides payment technology and software solutions for card, check, and digital-based payments in the Americas, Europe, and the Asia-Pacific. It operates through two segments, Merchant Solutions and Issuer Solutions. The Merchant Solutions segment offers authorization, settlement and funding, customer support, chargeback resolution, terminal rental, sales and deployment, payment security, and consolidated billing and reporting services. This segment also provides an array of enterprise software solutions that streamline business operations of its customers in various vertical markets; and value-added solutions and services, such as point-of-sale software, analytics and customer engagement, payroll and reporting, and human capital management. The Issuer Solutions segment offers solutions that enable financial institutions and retailers to manage their card portfolios through a platform; and commercial payments, account payables, and electronic payment alternatives solutions for businesses and governments. It markets its products and services through direct sales force, trade associations, agent and enterprise software providers, referral arrangements with value-added resellers, and independent sales organizations. The company was founded in 1967 and is headquartered in Atlanta, Georgia.

Healthcare Realty Trust NYSE:HR

$16.08 -0.11 (-0.65%)

Closing price 07/11/2025 03:58 PM Eastern

Extended Trading

$16.07 -0.02 (-0.09%)

As of 07/11/2025 05:48 PM Eastern

Healthcare Realty Trust, Inc. provides real estate investment services. It owns, leases, manages, acquires, finances, develops, and redevelops income-producing real estate properties associated primarily with the delivery of outpatient healthcare services throughout the United States of America. The company was founded by David R. Emery in 1992 and is headquartered in Nashville, TN.

JELD-WEN NYSE:JELD

$4.59 -0.06 (-1.29%)

Closing price 07/11/2025 03:59 PM Eastern

Extended Trading

$4.55 -0.04 (-0.96%)

As of 07/11/2025 04:28 PM Eastern

JELD-WEN Holding, Inc. designs, manufactures, and sells wood, metal, and composite materials doors, windows, and related building products in North America and Europe. The company offers a line of residential interior and exterior door products, including patio doors, and folding or sliding wall systems; non-residential doors; stile and rail doors; and wood, vinyl, and wood composite windows. It also provides other ancillary products and services, such as trim boards, glasses, hardware and locks, window screens, and molded door skins, as well as miscellaneous installation and other services. The company sells its products under the JELD-WEN, AuraLast, MiraTEC, Extira, LaCANTINA, MMI Door, Karona, ImpactGard, JW, Aurora, IWP, True BLU, ABS, Siteline, National Door, Low-Friction Glider, Hydrolock, VPI, AURALINE, FINISHIELD, MILLENNIUM, TRUFIT, EPICVUE, EVELIN, Swedoor, Dooria, DANA, Mattiovi, Zargag, Alupan, Domoferm, Kellpax, and HSE brands. It serves wholesale distributors and retailers, retail home centers, and building product dealers, as well as homebuilders, contractors, and consumers. JELD-WEN Holding, Inc. was founded in 1960 and is based in Charlotte, North Carolina.

Supernus Pharmaceuticals NASDAQ:SUPN

$33.12 -0.02 (-0.06%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$33.13 +0.01 (+0.03%)

As of 07/11/2025 04:11 PM Eastern

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare MarketRank™

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GPN, SUPN, JELD, HR, and ATVI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GPN, SUPN, JELD, HR, and ATVI Earnings

Compare Dividends

Latest GPN, SUPN, JELD, HR, and ATVI Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GPN, SUPN, JELD, HR, and ATVI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

GPN, SUPN, JELD, HR, and ATVI Company Descriptions

Activision Blizzard NASDAQ:ATVI

Global Payments NYSE:GPN

Healthcare Realty Trust NYSE:HR

JELD-WEN NYSE:JELD

Supernus Pharmaceuticals NASDAQ:SUPN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools